Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | foretinib | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0096 | 0.8 |
mRNA | Imatinib | GDSC1000 | pan-cancer | AAC | 0.017 | 0.8 |
mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | -0.0099 | 0.8 |
mRNA | SB-431542 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
mRNA | AZD-2281 | FIMM | pan-cancer | AAC | -0.045 | 0.8 |
mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |